HC Wainwright & Co. Reiterates Buy on NovoCure, Maintains $85 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on NovoCure (NASDAQ:NVCR) and maintained an $85 price target.
July 27, 2023 | 4:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NovoCure's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $85.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $85 indicates the firm's confidence in the company's potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100